

# Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

NCT07243782

---

**Status** RECRUITING  
**Sponsor** Novartis Pharmaceuticals  
**Enrollment** 76 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Hidradenitis suppurativa:
  - Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.
  - Patients who have agreed to participate in study (written informed consent)
  - Pediatric plaque psoriasis:
  - Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.
- ... and 4 more (see full listing online)

### Exclusion (2)

- Patients who are contraindicated according to national prescribing information
- Patients participating in other interventional clinical trials

## Locations (1 total)

---

Novartis Investigative Site, Seoul, Seoul, South Korea